Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) had Income from Continuous Operations of $-8.99M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.99M |
|
-- |
|
-- |
|
$9.57M |
|
$-9.57M |
|
$0.57M |
|
$-8.99M |
|
$-8.99M |
|
$-8.99M |
|
|
Income from Continuous Operations |
$-8.99M |
$-8.99M |
|
$-8.99M |
|
$-9.57M |
|
$-9.50M |
|
6.38M |
|
6.38M |
|
$-1.44 |
|
$-1.44 |
|
| Balance Sheet Financials | |
$13.43M |
|
$0.18M |
|
$0.39M |
|
$13.81M |
|
$1.48M |
|
-- |
|
-- |
|
$1.48M |
|
$12.33M |
|
$12.33M |
|
$12.33M |
|
4.71M |
|
| Cash Flow Statement Financials | |
$-11.13M |
|
$5.39M |
|
$7.16M |
|
$6.15M |
|
$7.56M |
|
$1.42M |
|
$0.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-72.93% |
|
-72.93% |
|
-65.12% |
|
-72.93% |
|
$2.62 |
|
$-1.75 |
|
$-1.75 |
|